Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma - 20/05/21
![](/templates/common/images/mail.png)
Abstract |
Background |
The impact of neoadjuvant chemotherapy (NAC) on overall and recurrence-free survival (OS, RFS) in resectable intrahepatic cholangiocarcinoma (ICC) is poorly characterized. We sought to investigate the association of NAC with oncologic outcomes in ICC.
Methods |
We identified n = 52 patients with ICC undergoing hepatectomy from 2004 to 2017. Oncologic outcomes were analyzed using Kaplan-Meier and multivariate Cox proportional hazard modeling.
Results |
The median patient age was 64-years. NAC was administered in ten (19%) patients, most commonly with gemcitabine-cisplatin (n = 8, 80%). Median RFS and OS were 15 months. and 49 months, respectively. Controlling for stage and margins, NAC was independently associated with improved OS (HR 0.16, P = 0.01) but not RFS (HR 0.54, P = 0.27). NAC was not associated with major post-operative complications (P = 0.25) or R1 margins (P = 0.58).
Conclusion |
NAC in ICC may hold oncologic benefits beyond downstaging borderline resectable disease, such as identifying patients with favorable biology who are more likely to benefit from resection.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Neoadjuvant chemotherapy in intrahepatic cholangiocarcinoma is associated with improved overall survival. |
• | Neoadjuvant chemotherapy is not associated with major post-operative complications or negative margins. |
• | Non-progression during neoadjuvant chemotherapy may signify more indolent disease biology that is more likely to benefit from resection. |
Keywords : Intrahepatic cholangiocarcinoma, Neoadjuvant chemotherapy, Resection, Hepatectomy, BILCAP
Plan
Vol 221 - N° 6
P. 1182-1187 - juin 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?